Your browser doesn't support javascript.
loading
Neutralizing immunity in vaccine breakthrough infections from the SARS-CoV-2 Omicron and Delta variants.
Servellita, Venice; Syed, Abdullah M; Morris, Mary Kate; Brazer, Noah; Saldhi, Prachi; Garcia-Knight, Miguel; Sreekumar, Bharath; Khalid, Mir M; Ciling, Alison; Chen, Pei-Yi; Kumar, G Renuka; Gliwa, Amelia S; Nguyen, Jenny; Sotomayor-Gonzalez, Alicia; Zhang, Yueyuan; Frias, Edwin; Prostko, John; Hackett, John; Andino, Raul; Wadford, Debra A; Hanson, Carl; Doudna, Jennifer; Ott, Melanie; Chiu, Charles Y.
Afiliação
  • Servellita V; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
  • Syed AM; Gladstone Institute of Data Science and Biotechnology, San Francisco, CA, USA; Innovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.
  • Morris MK; Viral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, CA, USA.
  • Brazer N; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
  • Saldhi P; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
  • Garcia-Knight M; Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA.
  • Sreekumar B; Gladstone Institutes, San Francisco, CA, USA.
  • Khalid MM; Gladstone Institutes, San Francisco, CA, USA.
  • Ciling A; Gladstone Institute of Data Science and Biotechnology, San Francisco, CA, USA; Innovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA.
  • Chen PY; Gladstone Institutes, San Francisco, CA, USA.
  • Kumar GR; Gladstone Institutes, San Francisco, CA, USA.
  • Gliwa AS; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
  • Nguyen J; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
  • Sotomayor-Gonzalez A; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
  • Zhang Y; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA.
  • Frias E; Abbott Laboratories, Abbott Park, IL, USA.
  • Prostko J; Abbott Laboratories, Abbott Park, IL, USA.
  • Hackett J; Abbott Laboratories, Abbott Park, IL, USA.
  • Andino R; Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA.
  • Wadford DA; Viral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, CA, USA.
  • Hanson C; Viral and Rickettsial Disease Laboratory, California Department of Public Health, Richmond, CA, USA. Electronic address: carl.hanson@cdph.ca.gov.
  • Doudna J; Gladstone Institute of Data Science and Biotechnology, San Francisco, CA, USA; Innovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA; Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA, USA; Department of Molecular and
  • Ott M; California Institute for Quantitative Biosciences (QB3), University of California, Berkeley, Berkeley, CA, USA; Gladstone Institutes, San Francisco, CA, USA; Department of Medicine, University of California, San Francisco, San Francisco, CA 94143, USA. Electronic address: melanie.ott@gladstone.ucsf.
  • Chiu CY; Department of Laboratory Medicine, University of California, San Francisco, San Francisco, CA, USA; UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA, USA; Innovative Genomics Institute, University of California, Berkeley, Berkeley, CA, USA; Department of Chemistry, University of
Cell ; 185(9): 1539-1548.e5, 2022 04 28.
Article em En | MEDLINE | ID: mdl-35429436
ABSTRACT
Virus-like particle (VLP) and live virus assays were used to investigate neutralizing immunity against Delta and Omicron SARS-CoV-2 variants in 259 samples from 128 vaccinated individuals. Following Delta breakthrough infection, titers against WT rose 57-fold and 3.1-fold compared with uninfected boosted and unboosted individuals, respectively, versus only a 5.8-fold increase and 3.1-fold decrease for Omicron breakthrough infection. Among immunocompetent, unboosted patients, Delta breakthrough infections induced 10.8-fold higher titers against WT compared with Omicron (p = 0.037). Decreased antibody responses in Omicron breakthrough infections relative to Delta were potentially related to a higher proportion of asymptomatic or mild breakthrough infections (55.0% versus 28.6%, respectively), which exhibited 12.3-fold lower titers against WT compared with moderate to severe infections (p = 0.020). Following either Delta or Omicron breakthrough infection, limited variant-specific cross-neutralizing immunity was observed. These results suggest that Omicron breakthrough infections are less immunogenic than Delta, thus providing reduced protection against reinfection or infection from future variants.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Humans Idioma: En Ano de publicação: 2022
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: SARS-CoV-2 / COVID-19 Limite: Humans Idioma: En Ano de publicação: 2022